Alkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ALKS
Alkermes plc (ALKS) EV/Sales
As of 16 October 2026, Alkermes plc (ALKS) trades at a EV/Sales of 4.6×. Over the past ten years it has ranged from 1.5× (March 2020) to 18.6× (December 2015); the current reading is higher than 63% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (12.06%) |
| FY2024 | 2.8× | 7.27% |
| FY2023 | 2.6× | (27.13%) |
| FY2022 | 3.5× | 18.16% |
| FY2021 | 3.0× | 10.40% |
| FY2020 | 2.7× | 7.45% |
| FY2019 | 2.5× | (36.23%) |
| FY2018 | 3.9× | (57.16%) |
| FY2017 | 9.2× | (17.11%) |
| FY2016 | 11.1× | (40.13%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.8× | 30.79% |
| Mar 2026 | 4.4× | 81.54% |
| Dec 2025 | 2.4× | (10.71%) |
| Sep 2025 | 2.7× | 2.36% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HIMS Hims & Hers Health, Inc. compare | 2.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc | 4.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)